Generic

Oncolytic virotherapy of breast cancer

Hartkopf A, Fehm T, Wallwiener D, Lauer U ...see all

Gynecologic Oncology, vol. 123, issue 1 (2011) pp. 164-171

  • 27

    Readers

    Mendeley users who have this article in their library.
  • 9

    Citations

    Citations of this article.
Sign in to save reference

Abstract

The use of replication competent viruses that selectively target and destroy cancer cells has rapidly evolved over the past decade and numerous innovative oncolytic viruses have been created. Many of these promising anti-cancer agents have recently entered into clinical trials (including those on breast cancer) and demonstrated encouraging safety and efficacy. Virotherapeutic strategies are thus of considerable interest to combat breast cancer in both (i) the primary disease situation in which relapse should be avoided as good as possible and (ii) in the metastatic situation which remains incurable to date. Here, we summarize data from preclinical and clinical trials using oncolytic virotherapy to treat breast cancer. This includes strategies to specifically target breast cancer cells, to arm oncolytic viruses with additional therapeutic transgenes and an outlining of future challenges when translating these promising therapeutics "from bench to bedside". © 2011 Elsevier Inc. All rights reserved.

Author-supplied keywords

  • Breast cancer
  • Oncolytic virus
  • Virotherapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Andreas D. Hartkopf

  • Tanja Fehm

  • Diethelm Wallwiener

  • Ulrich M. Lauer

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free